What Is Semax Peptide Used For?
Semax is a synthetic heptapeptide studied for cognition, attention, and neuroprotection. The name shows up beside nootropic stacks, stroke models, and optic nerve papers, often without a clear map of which claims the literature actually supports. This overview sorts those research uses. It is not a dosing guide and not medical advice.
What Semax is
Semax is the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It starts from ACTH 4-10, a short fragment of adrenocorticotropic hormone that was studied because it keeps some melanocortin signaling linked to learning, without the strong adrenal steroid release of full-length ACTH. Chemists then added a Pro-Gly-Pro tail. That tripeptide slows breakdown by peptidases, so Semax persists longer in biological media than the bare ACTH fragment. Molecular weight is about 813 daltons. The dry peptide is water soluble and is stored lyophilized.
The compound was developed in Russia and has a registered nasal formulation in that country. Outside that setting it is handled as a research chemical. A registered drug history is background, not permission to use a research vial. Sequence notes, routes, and research-reported ranges are collected on the Semax protocol page.
Cognitive and attention research
The widest research use is cognitive. Rodent learning tasks and a body of Russian clinical reports describe effects on memory consolidation, attention, and mental fatigue. Several groups report higher brain-derived neurotrophic factor (BDNF) in the hippocampus and basal forebrain after Semax exposure, along with changes in nerve growth factor signaling. BDNF is a plasticity marker, not proof that a person will think faster. It is still the finding most often cited when Semax is grouped with nootropic peptides.
Dopamine and serotonin turnover also shift in some animal studies. That fits a mildly activating profile: more exploratory behavior, not sedation. The useful contrast is Selank, a tuftsin-derived peptide researched mainly in anxiety models. How those two are discussed in research logs is covered in the Selank peptide dose notes. Figures there are research-reported, not instructions.
Stroke and ischemia models
A second, tighter literature is cerebral ischemia. In rat models of focal brain ischemia, Semax has been associated with smaller injury measures and better neurological scores in the days after vessel occlusion. Gene-expression work from the same line reports changes in immune, vascular, and trophic transcripts in the injured hemisphere. That is a network effect, not a single receptor switch.
Russian clinical papers discuss nasal Semax in acute ischemic stroke and transient ischemic attacks, framed as an add-on to ordinary hospital care in those studies, not as a replacement for it. Large Western multicenter trials are still scarce. Read the stroke papers as neuroprotection research. They are not evidence that a research peptide belongs in emergency treatment.
Optic nerve research
Lower-concentration Semax solutions have been studied in Russia for optic nerve disease, including neuritis and atrophy. The rationale is trophic signaling applied to retinal ganglion cells. Replication outside that literature is thin. Connective-tissue questions belong with BPC-157 protocols, not an ACTH fragment.
What it is not used for
Semax is not a growth-hormone secretagogue. It does not sit with ipamorelin or CJC-1295, which are studied for GH pulses, and it is not IGF-1 LR3 acting downstream of that axis. It is also not a mitochondrial peptide in the sense of MOTS-c or SS-31. Claims that Semax is for fat loss, muscle gain, or tendon repair are outside the published use pattern.
A common point of confusion is the modified analog. N-Acetyl Semax Amidate adds an N-terminal acetyl group and a C-terminal amide, changes suppliers describe as stability tweaks. The parent peptide still has the larger published record. The two are not interchangeable. The differences are spelled out in the N-Acetyl Semax Amidate review.
How research material is prepared
Published work and supplier protocols use two routes: intranasal solution and subcutaneous injection. Intranasal is the historical route for central-nervous-system questions, because the research interest is the brain rather than a systemic hormone pulse. Plasma exposure of the peptide itself is brief. Interest sits in downstream gene expression, which can outlast the peptide in blood.
Reconstitution is aqueous. Bacteriostatic water is used for injection experiments, and sterile saline for an intranasal drop. The peptide calculator turns a stated amount, vial size, and diluent volume into a syringe marking. Dry vials are typically kept frozen. Once mixed, solutions are refrigerated and used within a short research window. That is lab handling, not a recommendation to administer the compound.
Research contexts at a glance
The table below maps topics that appear in the Semax literature. Rows are study themes. They are not suggested uses.
| Research context | What papers actually examine | Evidence weight |
|---|---|---|
| Attention and memory | BDNF and NGF expression, learning tasks, small clinical series | Moderate, mostly preclinical and Russian reports |
| Ischemic stroke models | Injury size, neuro scores, gene expression after occlusion | Preclinical plus limited clinical series |
| Optic nerve disease | Neuritis and atrophy series using a nasal solution | Limited and region-specific |
| Anxiety comparison | Often a contrast with Selank, not a primary Semax claim | Indirect |
| GH release, fat loss, tendon repair | Not Semax endpoints | Not supported |
Limits and reported tolerability
Clinical summaries from Russia generally describe Semax as well tolerated. Occasional notes include nasal irritation, headache, and restlessness. Because the profile can feel activating, sleep disruption appears more often in anecdotal research logs than in formal adverse-event tables. Long-term safety, drug interactions, and use in pregnancy are not established to the standard a regulator outside its country of registration would expect.
Taken together, the record is a stable ACTH fragment, BDNF-linked signals, and a neuroprotection literature that is geographically narrow. Keep it inside a research-use-only frame.